Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Prostate Cancer

Free Subscription 30.09.2024 5 BJU Int 2 BMC Cancer 1 BMC Urol 1 Br J Cancer 2 Cancer 2 Clin Cancer Res 1 Clin Med Insights Oncol 8 Eur Urol 1 Genes Chromosomes Cancer 3 Int J Radiat Oncol Biol Phys 2 Int J Urol 1 J Natl Cancer Inst 1 J Nucl Med 2 N Engl J Med 1 PLoS One 1 Proc Natl Acad Sci U S A 3 Prostate 1 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BJU Int

1. FANG AM, Gregg JR, Pettaway C, Ma J, et al
   Whole-body MRI for staging prostate cancer: a narrative review.
   BJU Int. 2024 Sep 22. doi: 10.1111/bju.16514.
   PubMed         Abstract available
   
   
2. GONZALEZ-SAN SEGUNDO C, Lopez Campos F, Gomez Iturriaga A, Rodriguez A, et al
   A randomised trial of short- vs long-term androgen deprivation with salvage radiotherapy for biochemical failure following radical prostatectomy: URONCOR 06-24.
   BJU Int. 2024;134:568-577.
   PubMed         Abstract available
   
   
3. KINNEAR N, Fonseca PC, Ogbechie C, Adam S, et al
   Impact of frozen section on long-term outcomes in robot-assisted laparoscopic prostatectomy.
   BJU Int. 2024;134:608-614.
   PubMed         Abstract available
   
   
4. TAYA M, Behr SC, Westphalen AC
   Perspectives on technology: Prostate Imaging-Reporting and Data System (PI-RADS) interobserver variability.
   BJU Int. 2024;134:510-518.
   PubMed         Abstract available
   
   
5. SAHNI DS, Morrison J, Leung HY
   Grid-based cognitive diagnostic prostatic biopsy without transrectal ultrasonography.
   BJU Int. 2024;134:659-663.
   PubMed        
   
   

   
   BMC Cancer

6. ZHU Z, Zhu Y, Shi H, Zhou P, et al
   Efficacy of brachytherapy versus radical prostatectomy for localized prostate cancer-propensity score-matched comparison.
   BMC Cancer. 2024;24:1177.
   PubMed         Abstract available
   
   
7. DONG J, Ji R, Cui L, Liu G, et al
   Feasibility, safety and effectiveness of robot-assisted radical prostatectomy with a new robotic surgical system: a prospective, controlled, randomized clinical trial.
   BMC Cancer. 2024;24:1194.
   PubMed         Abstract available
   
   

   
   BMC Urol

8. WANG CJ, Qin J, Liu Y, Wen Z, et al
   Perioperative, functional, and oncologic outcomes in obese patients undergoing Da Vinci robot-assisted radical prostatectomy: a systematic review and meta-analysis.
   BMC Urol. 2024;24:207.
   PubMed         Abstract available
   
   

   
   Br J Cancer

9. CHOW ST, Fan J, Zhang X, Wang Y, et al
   Nuclear receptor TLX functions to promote cancer stemness and EMT in prostate cancer via its direct transactivation of CD44 and stem cell-regulatory transcription factors.
   Br J Cancer. 2024 Sep 26. doi: 10.1038/s41416-024-02843.
   PubMed         Abstract available
   
   

   
   Cancer

10. ZHENG R, Daniels JP, Moreira DM, Eslamimehr S, et al
    Does insulin resistance predict prostate cancer? Results from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial.
    Cancer. 2024 Sep 27. doi: 10.1002/cncr.35568.
    PubMed         Abstract available
    
    
11. NIERENGARTEN MB
    Androgen receptor signaling inhibitors linked to increased risk of cardiovascular adverse events in prostate cancer.
    Cancer. 2024;130:3399.
    PubMed        
    
    

    
    Clin Cancer Res

12. ISAACSSON VELHO P, Bastos DA, Saint'ana PT, Rigatti B, et al
    Nivolumab in patients with metastatic castration-resistant prostate cancer with and without DNA repair defects.
    Clin Cancer Res. 2024 Sep 27. doi: 10.1158/1078-0432.CCR-24-1595.
    PubMed         Abstract available
    
    
13. CHOU J, Robinson TM, Egusa EA, Lodha R, et al
    Synthetic Lethal Targeting of Cyclin Dependent Kinase-12-Deficient Prostate Cancer with PARP Inhibitors.
    Clin Cancer Res. 2024 Sep 25. doi: 10.1158/1078-0432.CCR-23-3785.
    PubMed         Abstract available
    
    

    
    Clin Med Insights Oncol

14. YU EM, Patel I, Hwang MW, Polani F, et al
    The Rapidly Evolving Treatment Landscape of Metastatic Hormone-Sensitive Prostate Cancer.
    Clin Med Insights Oncol. 2024;18:11795549241277181.
    PubMed         Abstract available
    
    

    
    Eur Urol

15. UNTERRAINER M, Unterrainer LM, Ilhan H
    Re: Robert Seifert, Louise Emmett, Steven P. Rowe, et al. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol 2023;83:405-12.
    Eur Urol. 2024 Sep 23:S0302-2838(24)02617-4. doi: 10.1016/j.eururo.2024.
    PubMed        
    
    
16. KLUMPER N, Eckstein M
    Reply to Feng Qi's Letter to the Editor re: Niklas Klumper, Viktor Grunwald, Arndt Hartmann, et al. The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy
    Eur Urol. 2024 Sep 23:S0302-2838(24)02616-2. doi: 10.1016/j.eururo.2024.
    PubMed        
    
    
17. RATHKOPF DE, Roubaud G, Chi KN, Efstathiou E, et al
    Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial.
    Eur Urol. 2024 Sep 23:S0302-2838(24)02594-6. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available
    
    
18. DAI YH, Chen PH, Lee DJ, Andrade G, et al
    A Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and Quality of Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy Utilising Lutetium-177 and Actinium-225 in Metastatic Prostate Cancer.
    Eur Urol. 2024 Sep 25:S0302-2838(24)02608-3. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available
    
    
19. VAN DEN BERGH RCN, Schoots IG, Cornford PA
    Standard Repeat Biopsies During Active Surveillance for Prostate Cancer: Are They Necessary in the Magnetic Resonance Imaging Era?
    Eur Urol. 2024 Sep 25:S0302-2838(24)02607-1. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available
    
    
20. QI F
    Re: Niklas Klumper, Viktor Grunwald, Arndt Hartmann, et al. The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy in Castration-resistant Prostate Cancer
    Eur Urol. 2024 Sep 25:S0302-2838(24)02612-5. doi: 10.1016/j.eururo.2024.
    PubMed        
    
    
21. CARLSSON SV, Lilja H, Vickers AJ, Bjartell AS, et al
    Re: Early Prostate Cancer Deaths Among Men with Higher vs Lower Genetic Risk.
    Eur Urol. 2024 Sep 25:S0302-2838(24)02615-0. doi: 10.1016/j.eururo.2024.
    PubMed        
    
    
22. GANDAGLIA G, Barletta F, Briganti A, Montorsi F, et al
    Re: Long-term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients with Low-Risk Prostate Cancer.
    Eur Urol. 2024 Sep 26:S0302-2838(24)02613-7. doi: 10.1016/j.eururo.2024.
    PubMed        
    
    

    
    Genes Chromosomes Cancer

23. NEYAZ A, Furlan A, Karunamurthy A, John I, et al
    Spindle Cell Rhabdomyosarcoma of the Prostate With ZFP64::NCOA2 Fusion.
    Genes Chromosomes Cancer. 2024;63:e23274.
    PubMed        
    
    

    
    Int J Radiat Oncol Biol Phys

24. OST P, Mottet N
    PSMA PET-CT, When Seeing Becomes Improving.
    Int J Radiat Oncol Biol Phys. 2024;120:646-647.
    PubMed        
    
    
25. MURPHY DG, Emmett L
    PSMA PET Staging is Advised for All High-Risk Patients With Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2024;120:642-645.
    PubMed        
    
    
26. MANNAR D, Liu W
    When Seeds Fail: Local Recurrence of Prostate Cancer Within a Seminal Vesicle After Brachytherapy.
    Int J Radiat Oncol Biol Phys. 2024;120:621-623.
    PubMed        
    
    

    
    Int J Urol

27. GUO X, Zhang F, Hao G
    Causal relationship between folic acid and prostate cancer risk: Insights from Mendelian randomization analysis.
    Int J Urol. 2024 Sep 22. doi: 10.1111/iju.15565.
    PubMed         Abstract available
    
    
28. MITSUI Y, Nakajima K
    Editorial Comment to "Causal relationship between folic acid and prostate cancer risk: Insights from Mendelian randomization analysis".
    Int J Urol. 2024 Sep 26. doi: 10.1111/iju.15582.
    PubMed        
    
    

    
    J Natl Cancer Inst

29. EL KHOURY CJ, Freedland SJ, Gandhi K, Keith SW, et al
    Disparities in the Utilization of MRI for Prostate Cancer Detection: A Population-Based Study.
    J Natl Cancer Inst. 2024 Sep 23:djae234. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Nucl Med

30. MURTHY V, Voter AF, Nguyen K, Allen-Auerbach M, et al
    Efficacy and Toxicity of [(177)Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data.
    J Nucl Med. 2024 Sep 26:jnumed.124.267816. doi: 10.2967/jnumed.124.267816.
    PubMed         Abstract available
    
    

    
    N Engl J Med

31. HUGOSSON J, Godtman RA, Wallstrom J, Axcrona U, et al
    Results after Four Years of Screening for Prostate Cancer with PSA and MRI.
    N Engl J Med. 2024;391:1083-1095.
    PubMed         Abstract available
    
    
32. PINSKY PF
    Prostate Biopsy in Men with an Elevated PSA Level - Reducing Overdiagnosis.
    N Engl J Med. 2024;391:1153-1154.
    PubMed        
    
    

    
    PLoS One

33. SALVIOLI M, Vandelaer L, Baena E, Schneider K, et al
    The effect of tumor composition on the success of adaptive therapy: The case of metastatic Castrate-Resistant Prostate Cancer.
    PLoS One. 2024;19:e0308173.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

34. WANG Z, Yu H, Bao W, Qu M, et al
    Proteomic and phosphoproteomic landscape of localized prostate cancer unveils distinct molecular subtypes and insights into precision therapeutics.
    Proc Natl Acad Sci U S A. 2024;121:e2402741121.
    PubMed         Abstract available
    
    

    
    Prostate

35. MURTA CB, Junior JP, de Souza Filho PHF, de Godoy Junior PC, et al
    Prostate cancer focal therapy: surgeon experience influences oncological results.
    Prostate. 2024 Sep 26. doi: 10.1002/pros.24800.
    PubMed         Abstract available
    
    
36. TRAN EU, Ovruchesky E, Yamamoto K, Marley S, et al
    Bipolar androgen therapy for treatment of metastatic castration-resistant prostate cancer: A case series.
    Prostate. 2024 Sep 22. doi: 10.1002/pros.24798.
    PubMed         Abstract available
    
    
37. WONG CH, Ko IC, Leung DK, Siu B, et al
    Deep PSA response and extended time-to-nadir as robust predictors of survival in Asian patients with de novo metastatic hormone-sensitive prostate cancer receiving upfront intensified treatment.
    Prostate. 2024 Sep 19. doi: 10.1002/pros.24797.
    PubMed         Abstract available
    
    

    
    Urology

38. QUALKENBUSH E, Perry AG, Kumar N, Thomas CS, et al
    Virtual reality as an adjunct to traditional patient counseling in patients with newly-diagnosed localized prostate cancer.
    Urology. 2024 Sep 20:S0090-4295(24)00819-7. doi: 10.1016/j.urology.2024.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.